Ketek in CAP / AECB in Ambulatory Adult Patients

Community Acquired Pneumonia (CAP) Clinical Trial

Official title:
A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator

Status Completed

Clinical Trial Summary

To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Acute Exacerbation of Chronic Bronchitis (AECB)
Bronchitis
Bronchitis, Chronic
Community Acquired Pneumonia (CAP)
Pneumonia

Clinical Trial Details

NCT number	NCT00546676
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 4
Start date	May 2004
Completion date	December 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01293435` - Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections	N/A
Completed	`NCT04613375` - PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Completed	`NCT00809328` - The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)	Phase 3